Format

Send to

Choose Destination
Endocrinol Metab Clin North Am. 2006 Sep;35(3):491-510, vii-viii.

Diabetic dyslipidemia.

Author information

1
Department of Medicine, College of Physicians and Surgeons of Columbia University, PH 10-305, 630 West 168th Street, New York, NY 10032, USA.

Abstract

Type 2 diabetes mellitus is associated with a markedly increased risk of cardiovascular disease. A complex dyslipidemia, which is an integral part of the underlying insulin resistance in this group, is a key to this increased risk. Increased secretion of VLDL from the liver is a central feature of dyslipidemia and is linked significantly to the low HDL and abnormal LDL that are also present. A number of physiologic and pharmacologic approaches are available and should be used aggressively to treat diabetic dyslipidemia.

PMID:
16959582
DOI:
10.1016/j.ecl.2006.06.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center